MaxCyte

Update in progress

MXCT (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

MaxCyte, Inc. is a life sciences company that discovers, develops, and commercializes cell therapies for U.S. and international markets. Its ExPERT platforms include ATx (static transfection), STx (flow transfection for protein production and cell assays), GTx (large‑scale transfection), and VLx (very large‑volume engineering). It sells instruments, disposables, buffers, and software protocols, and licenses technology to developers, pharma, and biotech. Founded 1998; based in Rockville, Maryland.

Company score

Sentiment: 0.24; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.14; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.15; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive